Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: The impact of KRAS mutations on VEGF-A production and tumour vascular network

Figure 3

Functional analysis of VEGF-A PROMOTER. A) ASP13 or CYS12 cells were treated with actinomycin D. After the time indicated mRNA was obtained and VEGF-A mRNA levels measured by RT-PCR. Results are the average of two independent experiments. No differences in VEGF-A mRNA stability were observed in ASP13 or CYS12 cells. B) Luciferase activities after transfection of the complete VEGF-A promoter (Construct 1) or two partial deletions (Construct 2 and 3). VEGF-A promoter activity was increased for all constructs in Asp13 when compared to CYS12 transfectants. Promoter activity was decreased after deletion of the AP2/Sp1 response elements in ASP13 cells (P < 0.011). Results are the average ± SE of four independent experiments.

Back to article page